Terns' TERN-201 Phase 1b AVIATION trial meets safety; no efficacy in NASH

Terns Pharmaceuticals, Inc.

Part 1 of Phase 1b AVIATION trial of TERN-201 10 mg met primary safety endpoint; well-tolerated with no SAEs.
No meaningful changes in exploratory NASH biomarkers (cT1, ALT, AST, GGT, CK-18) vs placebo.
Near complete (>98%) VAP-1 inhibition achieved but no efficacy signals.
Part 2 (20 mg) ongoing; top-line results expected H2 2022.
Cash runway into 2024; pipeline includes TERN-501 Phase 2a in H1 2022 and TERN-601 Phase 1 in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.